We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

2o9i

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:2o9i.gif|left|200px]]
+
{{Seed}}
 +
[[Image:2o9i.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2o9i| PDB=2o9i | SCENE= }}
{{STRUCTURE_2o9i| PDB=2o9i | SCENE= }}
-
'''Crystal Structure of the Human Pregnane X Receptor LBD in complex with an SRC-1 coactivator peptide and T0901317'''
+
===Crystal Structure of the Human Pregnane X Receptor LBD in complex with an SRC-1 coactivator peptide and T0901317===
-
==Overview==
+
<!--
-
The human pregnane X receptor (PXR) recognizes a range of structurally and chemically distinct ligands and plays a key role in regulating the expression of protective gene products involved in the metabolism and excretion of potentially harmful compounds. The identification and development of PXR antagonists is desirable as a potential way to control the up-regulation of drug metabolism pathways during the therapeutic treatment of disease. We present the 2.8A resolution crystal structure of the PXR ligand binding domain (LBD) in complex with T0901317 (T1317), which is also an agonist of another member of the orphan class of the nuclear receptor superfamily, the liver X receptor (LXR). In spite of differences in the size and shape of the receptors' ligand binding pockets, key interactions with this ligand are conserved between human PXR and human LXR. Based on the PXR-T1317 structure, analogues of T1317 were generated with the goal of designing an PXR antagonist effective via the receptor's ligand binding pocket. We find that selectivity in activating PXR versus LXR was achieved; such compounds may be useful in addressing neurodegenerative diseases like Niemann-Pick C. We were not successful, however, in producing a PXR antagonist. Based on these observations, we conclude that the generation of PXR antagonists targeted to the ligand binding pocket may be difficult due to the promiscuity and structural conformability of this xenobiotic sensor.
+
The line below this paragraph, {{ABSTRACT_PUBMED_17215127}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 17215127 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_17215127}}
==About this Structure==
==About this Structure==
Line 28: Line 32:
[[Category: Pxr]]
[[Category: Pxr]]
[[Category: T0901317]]
[[Category: T0901317]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 10:29:26 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 04:23:01 2008''

Revision as of 01:23, 28 July 2008

Image:2o9i.png

Template:STRUCTURE 2o9i

Crystal Structure of the Human Pregnane X Receptor LBD in complex with an SRC-1 coactivator peptide and T0901317

Template:ABSTRACT PUBMED 17215127

About this Structure

2O9I is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism., Xue Y, Chao E, Zuercher WJ, Willson TM, Collins JL, Redinbo MR, Bioorg Med Chem. 2007 Mar 1;15(5):2156-66. Epub 2006 Dec 20. PMID:17215127

Page seeded by OCA on Mon Jul 28 04:23:01 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/2o9i"
Personal tools